Androgen deprivation therapy (ADT) is the standard of care for patients with metastatic prostate cancer (mPC). However, nearly all patients with mPC progress to castration-resistant PC (CRPC). Arrays of treatments, including secondary hormonal therapies, are available for the treatment of mPC and CRPC, which show efficacy when administered with ADT.
Continuation of ADT is recommended for CRPC treatment as therapies are added. New secondary hormonal therapies include abiraterone, targeting the CYP17 enzyme family, and enzalutamide, an androgen receptor inhibitor with heightened binding specificity. The optimal decision-making process for CRPC treatment option remains unclear, pending further research and experience.
Urology 2015 Aug 14 [Epub ahead of print]
Fred Saad, Karim S Fizazi
Centre de Hospitalier de Université de Montréal, Montréal, Canada Electronic address: fred saad@umontreal ca , Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, 94805, France